Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine EdurantBasic HIV Primary Care
You are just a few steps away from free CE credits!
1
Sign in or Register
A free account is required.
2
Study the Material
An entire Cc section, or just a few topics at a time.
3
Take the CE Quiz
5 questions covering the topics in each Cc section.
4
Claim CE Credit
Free CNE and Free CME available!
Section Navigation
Section Navigation
- Lesson 7 Overview
Substance Use Disorders - 0%Topic 1
BackgroundActivities - 0%Topic 2
Screening for Substance Use DisordersActivities - 0%Topic 3
Epidemiology of Substance Use in United StatesActivities - 0%Topic 4
Substance Use Disorders in People with HIVActivities - 0%Topic 5
Alcohol Use DisorderActivities - 0%Topic 6
Cannabis Use DisorderActivities - 0%Topic 7
Hallucinogen Use DisorderActivities - 0%Topic 8
Opioid Use DisorderActivities - 0%Topic 9
Stimulant Use DisorderActivities - 0%Topic 10
Tobacco Use DisorderActivities - 0%Topic 11
Summary PointsActivities - Substance Use Disorders CE Quiz
Substance Use Disorders Overview
About this Lesson
Last Updated: February 3rd, 2025
CNE/CME Continuing Education
This lesson qualifies for:
View CE Notices
- 2 CME AMA PRA Category 1 Credits™, or
- 2 CNE contact hours and 2 CE contact hours (does NOT qualify for pharmacology CE for advanced practice nurses)
CNE and CME Origination: May 1st, 2017
CNE and CME Review: September 1st, 2023
CNE and CME Expiration: August 31st, 2026 (3rd Edition)
View CE Notices
Steps to Acquire CE for this Lesson:
1
Quiz
Score 80%+
2
Give Feedback
Complete survey
3
Print CE Certificate
Obtain proof of CE3rd Edition
This is a substantial revision of the original Lesson. The previous edition was titled Substance Use Disorders and available until September 1st, 2023.
Learning Objectives
- Discuss the resources available to screen for different substance use disorders
- Explore the epidemiology of substance use disorders in the United States
- Describe the unique impact that substance use disorders have on persons with HIV
- Explain the rationale for employing behavioral, psychosocial, and pharmacotherapy interventions in treating common substance use disorders
- Define the concept of harm reduction as related to treating substance use disorders
Lesson Contributors
Authors
Maria A. Corcorran, MD, MPH
Maria A. Corcorran, MD, MPH
Assistant Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Assistant Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Disclosures:
None
Jehan Z. Budak, MD
Jehan Z. Budak, MD
Assistant Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Assistant Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Disclosures:
None
Reviewers
David H. Spach, MD
David H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Disclosures:
None
Lesson Plan
Quick Reference View
A single document for easy access to every topic in the self-study modules.
PDF version also available.
No sign-in required for Quick Reference
Question Bank
Interactive board-review style questions about Epidemiology of HIV.
CNE/CME CME+MOC credits and CNE contact hours available.